The Effects of Matrix Metalloproteinase-9 on CX3CL1 Shedding and Axon Retraction by Dobrie, Lauren A
University of Central Florida 
STARS 
Honors Undergraduate Theses UCF Theses and Dissertations 
2019 
The Effects of Matrix Metalloproteinase-9 on CX3CL1 Shedding 
and Axon Retraction 
Lauren A. Dobrie 
University of Central Florida 
 Part of the Nervous System Commons, and the Neurology Commons 
Find similar works at: https://stars.library.ucf.edu/honorstheses 
University of Central Florida Libraries http://library.ucf.edu 
This Open Access is brought to you for free and open access by the UCF Theses and Dissertations at STARS. It has 
been accepted for inclusion in Honors Undergraduate Theses by an authorized administrator of STARS. For more 
information, please contact STARS@ucf.edu. 
Recommended Citation 
Dobrie, Lauren A., "The Effects of Matrix Metalloproteinase-9 on CX3CL1 Shedding and Axon Retraction" 
(2019). Honors Undergraduate Theses. 506. 
https://stars.library.ucf.edu/honorstheses/506 
  
 
THE EFFECTS OF MATRIX METTALOPROTEINASE-9  
ON CX3CL1 SHEDDING AND AXON RETRACTION 
 
 
 
by 
 
LAUREN A. DOBRIE 
 
 
 
A thesis submitted in partial fulfillment of the requirements  
for the Honors in the Major Program in Biomedical Sciences  
in the College of Medicine  
and the Burnett Honors College  
at the University of Central Florida 
Orlando, Florida 
 
 
 
Spring Term, 2019 
 
   
Thesis Chair: Alicia Hawthorne, PhD 
 
 
 
 
  
ii 
 
ABSTRACT 
Spinal cord injury (SCI) often leads to irreversible damage, and permanent paralysis 
inferior to the injury is common (Leibinger et al., 2013). Injury to the spinal cord occurs in two 
phases. In the first phase, components of the spinal cord are subject to mechanical trauma 
causing direct damage. In the second phase, damage spreads from the area of injury through 
molecular processes. Several studies have linked M1 “pro-inflammatory” macrophages to 
exacerbation of damage by inducing dieback of dystrophic axons, but not healthy axons, through 
direct cellular contact. Several studies have identified the presence of macrophage subtypes at 
specific time. A literature review was conducted in order to summarize these findings (Busch, 
Horn, Silver, & Silver, 2009; Evans et al., 2014; Horn, Busch, Hawthorne, van Rooijen, & 
Silver, 2008; Kigerl et al., 2009; Shechter et al., 2013). Although the full mechanism behind the 
process of M1 macrophage-mediated dieback of dystrophic axons is unclear, matrix 
metalloproteinase-9 (MMP-9) produced by these macrophages has been shown to play a role. 
However, the specific interaction between MMP-9 and neurons is under investigation. The 
research described explores the relationship between MMP-9 and fractalkine (CX3CL1), a 
surface protein expressed by CNS neurons. SDS-PAGE and western blot were used to determine 
whether the presence of MMP-9 increases the cleavage of fractalkine at several time intervals. At 
a concentration of 300ng/ml, MMP-9 was not found to demonstrate cleavage of fractalkine.  
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BACKGROUND 
Spinal Cord Injury and Barriers to Growth 
Spinal cord injury (SCI) often leads to irreversible damage, and permanent paralysis 
inferior to the injury is common (Leibinger et al., 2013). Injury to the spinal cord occurs in two 
phases. In the first phase, components of the spinal cord are subject to mechanical trauma 
causing direct damage. In the second phase, damage spreads from the area of injury through 
molecular processes. Increased blood brain barrier (BBB) permeability, inflammation, and the 
presence of other factors in the extracellular matrix (ECM) disrupt the microenvironment and 
increase damage. By this process, axonal retraction and cell death occurs not only in neurons 
subjected to the initial damage, but also to neurons in the surrounding areas (Donnelly & 
Popovich, 2008; Garcia, Aguilar-Cevallos, Silva-Garcia, & Ibarra, 2016).  
 When approaching the problem of axon regeneration in severed neurons, internal and 
external factors must be considered. Intrinsically, adult mammalian neurons show little plasticity 
in comparison to embryonic neurons. Differences in expression patterns hinder growth in mature 
cells; these differences have many causes, such as epigenetic regulation through histone 
acetylation. In fact, several experimental drugs targeting histone deacetylases (HDACs) have 
shown success in promoting neuron growth during pre-clinical trials. Inhibiting HDACs to favor 
acetylation of certain histone tails allows growth-promoting genes to be more accessible for 
transcription (Ganai, Ramadoss, & Mahadevan, 2016).  
Extrinsically, a major barrier to axon regeneration after spinal cord injury is the glial scar, 
formed primarily by astrocytes upon CNS damage and breach of the blood brain barrier. The 
glial scar benefits damaged tissue by segregating it and preventing further damage, but it is a 
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large obstacle to successful repair. Not only does the glial scar present a physical barrier to 
growth, but it also contains inhibitory components such as proteoglycans (Silver & Miller, 2004).  
Proteoglycans, such as chondroitin sulfate proteoglycans (CSPGs), are found in highest 
concentrations at the epicenter of the injury. Neurons are able to grow in the presence of 
proteoglycans until the concentration becomes too high, at which point growth is halted (Tom, 
Steinmetz, Miller, Doller, & Silver, 2004). In vitro studies have shown success in promoting 
neurite outgrowth through enzymatic cleavage of proteoglycan side chains, although this growth-
promoting effect is reduced in the absence of growth factors (Kigerl et al., 2009; Silver & Miller, 
2004). Regeneration capabilities are regulated by a complex network of interactions among 
growth factors, inhibitors, ECM, and neuronal expression profiles. Expanding current knowledge 
about these interactions is crucial to developing new treatments for SCI.   
Degeneration and Regeneration of Axons 
At the site of injury, both neurite length and the growth cone shape are indicative of the 
state of neuron growth. In the environment of the glial scar, growth cones become dystrophic 
when a certain concentration of inhibitory molecules is reached. Described by Ramon y Cajal as 
“sterile clubs” due to their irregular shape, dystrophic end bulbs lose their ability to extend 
(Silver & Miller, 2004). Although they do not appear to be growing, it is interesting that these 
ends are constantly turning over their membrane. The lack of linear growth is not permanent, 
however; experimentally, neurons transferred from an inhibitory to a growth-promoting 
environment are able to begin growth once more (Silver & Miller, 2004; Tom et al., 2004).  
In adult mammalian neurons, axotomy will not normally result in apoptosis if the cut site 
is far enough from the soma. When a neuron is severed at an appropriate distance, an influx of 
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calcium propagates from the site of axon damage to the soma. This influx leads first to growth 
cone collapse, followed by a latency period (Kilinc et al., 2011). Activation of several enzymes, 
including calpain and HDACs, leads to disassembly of the cytoskeleton. (Ganai et al., 2016; 
Kilinc et al., 2011). This Wallerian degeneration, characterized by the cytoskeleton disassembly 
distal to the axotomy site and phagocytosis of axonal fragments by glial cells and macrophages, 
proceeds in an anterograde fashion. In uninjured neurons, a phenomenon known as dieback may 
occur by a similar process in response to environmental factors or disease states, usually in a 
retrograde fashion (Kilinc et al., 2011).  
For a short time after injury, the shortened axonal end, or “dystrophic endbulb,” will 
attempt to sprout and regenerate (Evans et al., 2014). However, the extracellular environment is 
largely inhibitory and poses several obstacles to sprouting. After Wallerian degeneration and 
formation of dystrophic endbulbs in the first few hours after injury, dieback occurs, during which 
axons are retracted toward the soma (Busch et al., 2009). Studies indicate that although the initial 
retraction is due to intrinsic mechanisms, there is a secondary retraction phase likely mediated by 
direct cellular contact with blood-derived macrophages approximately 4 to 7 days post-injury 
(Busch et al., 2009; Evans et al., 2014). 
The Role of Microglia and Blood-Derived Macrophages 
 Microglia residing in the central nervous system function in local immunity, synaptic 
maintenance, and phagocytosis of debris (Smith, Hagberg, Naylor, & Mallard, 2014). After SCI, 
microglia react immediately to damage (Evans et al., 2014). After approximately 3-4 days, 
blood-derived macrophages infiltrate the site of injury (Garcia et al., 2016; Shechter et al., 2013). 
Both microglia and macrophages can exist as two different varieties. The M1 variety is 
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considered “pro-inflammatory” and has been shown to inhibit neurogenesis, while the M2 
variety is considered “anti-inflammatory” and promotes neurogenesis (Smith et al., 2014). M1 
macrophages are “classically activated” by molecules such as lipopolysaccharide (LPS) and 
interferon-γ (INFγ). M1 cells promote inflammation by releasing inflammatory cytokines and 
also produce oxidative molecules, which are effective when fighting infection and tumor cells 
but cause incidental damage to CNS tissue (Kigerl et al., 2009). Blood-derived monocytes that 
differentiate into M1 cells have experimentally been shown to extravasate through the spinal 
cord meninges at the site of injury, in contrast to those destined to be M2 cells that enter the CSF 
through the choroid plexus and migrate to the injury (Shechter et al., 2013). These M2 
macrophages are activated by cytokines such as IL-4 and IL-13 and promote tissue regrowth and 
extracellular matrix remodeling (Kigerl et al., 2009).  
 In typical injuries outside of the CNS, M1 cells enter the site of injury first to remove 
debris and induce apoptosis in damaged cells, followed by M2 cells that promote tissue 
regeneration and healing. In the CNS, this order is thought to be reversed, with M2 cells acting 
before being overwhelmed by M1 cells approximately 7 days post-injury. Several studies have 
used cell surface markers to track the dominance of each phenotype after SCI. The ratio of M1 to 
M2 cells significantly increases 7 days post-injury. It is thought that the microenvironment of the 
injury is responsible for this continuously elevated ratio. In one study, M2 macrophages were 
introduced into healthy and injured CNS tissue, and the M2 phenotype remained present only in 
the healthy tissue. It has been suggested that the high density of pro-inflammatory signals related 
to the injury, such as INFγ, are highly supportive of M1 differentiation and not M2 
differentiation  (Kigerl et al., 2009; Smith et al., 2014).  
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 It is also important to note the differences in macrophage recruitment to sites of injury in 
the brain and spinal cord. Although the relationship between neurons and macrophages can often 
be generalized, the role of macrophages is different in the brain and the spinal cord. In 
comparison to brain injury, recruitment of macrophages is much higher in SCI. Similarly, when 
pro-inflammatory cytokines were introduced to both the brain and the spinal cord in the absence 
of injury, it was found that more macrophages were recruited to the spinal cord. Furthermore, 
injection of the same inflammatory cytokine to both the brain and the spinal cord does not 
necessarily elicit recruitment of the same white blood cell variety to both sites (Donnelly & 
Popovich, 2008). 
 Aside from the effects macrophages have on glia at the site of injury, several recent 
studies have focused on the direct effects they may have on neurons. The patterns of axonal 
growth in the presence of M1 and M2 cells are quite different. Neurons in vitro introduced to M2 
macrophage-conditioned media (MCM) grew linearly for long distances, even in the presence of 
inhibitors such as CSPGs and myelin-associated glycoproteins. In contrast, those grown on M1 
MCM sprouted axons that were short and branched (Kigerl et al., 2009). Not only do M1 
macrophages limit growth, but direct contact with neurons may also induce dieback in dystrophic 
axons (Busch et al., 2009; Evans et al., 2014; Horn et al., 2008; Kigerl et al., 2009).  
There are several theories surrounding the neuroprotective role of M2 macrophages. M2 
cells are able to remove debris without causing damage to their surroundings via their CD206 
receptors. In vitro, upregulation of Arginase I in M2 cells leads to synthesis of polyamines that 
allow neurons to grow despite myelin inhibition (Kigerl et al., 2009). The anti-inflammatory 
cytokines secreted by M2 cells may also benefit neuronal health. In low doses, IL-4 and IL-10 
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have enhanced survival of severed nerves through STAT6 and STAT3 signaling, respectively 
(Vidal, Lemmens, Dooley, & Hendrix, 2013).  
 The mechanism by which M1 cells inhibit growth is also under investigation. As stated 
previously, oxidative molecules produced by M1 cells, including nitric oxide radicals, are 
damaging to CNS tissues (Kigerl et al., 2009). Interestingly, some inflammatory cytokines 
produced by M1 macrophages, such as IL-6, promote high levels of linear growth. In vitro 
growth of neurons in the presence of IL-6 resulted in higher survival rates than controls and 
longer growth at increasing concentrations. These neurons even grew in the presence of 
inhibition by CNS myelin extract (Leibinger et al., 2013). Data suggests that activation of the 
gp130 receptor via IL-6 leads to activation of the STAT3 and P13K/Akt pathways, which are 
highly growth-promoting. Conversely, inhibition of IL-6 has been shown to decrease growth.  
However, the effects of IL-6 activation of glial cells in the CNS ultimately leads to neuronal 
damage (Donnelly & Popovich, 2008; Leibinger et al., 2013). This illustrates the complications 
that may arise when attempting to selectively alter the immune system to enhance neuronal 
growth, as a system is more than the sum of its parts.  
 M1 macrophages have also been shown to induce a secondary phase of dieback of axons 
through direct contact with dystrophic end bulbs. Experimental depletion of blood-derived 
macrophages significantly reduced secondary phase dieback in vivo (Horn et al., 2008). 
Furthermore, treatment of macrophages with trypsin prior to exposure to neurons also decreased 
axon dieback, while treatment with MCM did not induce dieback. This data indicates that 
tethering contact is necessary for macrophages to induce dieback of dystrophic axons (Horn et 
al., 2008). Interestingly, blood monocyte-derived M1 macrophages seem to cause this dieback 
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nearly 100% of the time after contact, while microglia rarely have the same effect (Evans et al., 
2014; Horn et al., 2008). M1 cells possess the zinc-dependent metalloproteinase MMP-9, which 
is thought to be involved in axon dieback induced through cellular contact. Downregulation and 
inhibition of MMP-9 have been used to decrease dieback in vivo and in vitro. Metalloproteinase 
inhibition via GM6001 significantly reduced retraction during cellular contact. Inhibitors specific 
to MMP-9 such as minocycline had a similar effect in reducing dieback. This is in contrast to the 
inhibition of MMP-2 produced by M2 macrophages, which had no effect on dieback. MMP-9 
has been a target for several new drugs used to treat spinal cord injury, including the FDA-
approved methylprednisolone which suppresses MMP-9 (Busch et al., 2009). Administration of 
TGFα and IL-10 in vivo to downregulate MMP-9 were also beneficial to neuron growth (Garcia 
et al., 2016). Whether MMP-9 is directly involved in M1 contact with neurons or it simply 
contributes to the mechanism, it is apparent that the metalloproteinase is a key component in 
macrophage-mediated dieback of dystrophic axons after spinal cord injury. 
MMP-9 and Membrane Proteins 
  The effects of MMP-9 on neuron growth has been successfully linked to interactions 
with β1 integrins in vitro and in vivo. While treatment with MMP-9 did not alter the 
transcriptional expression of β1 integrin mRNA, western blot assay showed that exposure to 
MMP-9 significantly decreased the protein amounts in cells over time (Kim et al., 2009). The 
data from this study suggests that MMP-9 is involved in direct cleavage of β1 integrins, 
destabilizing neuronal interactions with the extracellular matrix. Furthermore, decreased 
interactions between integrins and the extracellular matrix may lead to a decrease in intracellular 
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signaling via the P13K/Akt pathway (Kim et al., 2009). Cleavage of β1 integrins would promote 
apoptosis and inhibit adhesion to the ECM. 
 Matrix metalloproteinases are thought also to interact with other transmembrane adhesion 
molecules, including several classes of integrins, cadherins, and cell adhesion molecules (CAM). 
In one study, neural cell adhesion molecule (NCAM) was suggested as a substrate of MMP-9, 
and MMP-9 proteolytic activity was linked to exacerbation of damage after ischemic injury 
(Shichi, Fujita-Hamabe, Harada, & Mizoguchi, 2011). In another study, MMP-7 was shown to 
cleave N-cadherin, while MMP-2 showed no significant cleavage (Conant et al., 2017). N-
cadherin, a type I cadherin involved in cell-to-cell adherence, was also shown to be shed from 
smooth muscle in response to the presence of MMP-9 (Dwivedi, Slater, & George, 2009).   
 Fractalkine (CX3CL1) is a chemokine commonly found on the surface of CNS neurons, 
but not in peripheral blood. According to Poniatowski et al., CX3CL1 is found throughout the 
CNS, most notably in the brain and in the dorsal horn of the spinal cord. Expression levels have 
been shown to vary with age as well as with certain pathological conditions (Poniatowski et al., 
2017). Its receptor, CX3CR1, is commonly found on macrophages, and can also be expressed on 
CNS neurons (Bazan et al., 1997; Horn et al., 2008). The mature, transmembrane form of 
CX3CL1 contains 373 amino acid residues with up to 26 O-glycosylations. At the N-terminal 
domain, residues 1-76 form a chemokine domain. The chemokine domain is bound to a 
transmembrane domain by a mucin stalk, with a dibasic cleavage site present just before the 
transmembrane domain. Finally, 37 residues form the intracellular C-terminal domain (Bazan et 
al., 1997).  
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The molecular weight of fractalkine is difficult to pinpoint. One study claims the mature 
protein has a molecular weight of approximately 17.5kDa, but can be found at molecular weights 
up to 95kDa after glycosylation (Poniatowski et al., 2017). Another study found bands on 
western blot corresponding to fractalkine at ~100kDa, ~95kDa, and ~85kDa. The study 
suggested that the ~100kDa fragment corresponded to the full transmembrane form of the 
protein, the ~95kDa fragment corresponded to the recycled form of the transmembrane protein, 
and the ~85kDa fragment corresponded to the cleaved soluble chemokine domain (Zieger, 
Ahnelt, & Uhrin, 2014). This soluble chemokine fragment was found to have relative molecular 
weight of 95kDa in other studies (Bazan et al., 1997). Cleavage fragments may be produced 
experimentally, but they are also naturally produced by metalloproteinases such as ADAM10 
and ADAM17 expressed by neurons (Dean & Overall, 2007; Poniatowski et al., 2017). The 
variability among these studies could be due to differences in cell types and experimental 
conditions (Zieger et al., 2014). However, each of these studies show that fractalkine can be 
found at a wide range of molecular weights due to glycosylations and natural cleavage by 
proteases.  
The membrane-bound form of CX3CL1 acts as an adhesion molecule for monocytes. 
Membrane-bound CX3CL1 can be cleaved by certain enzymes, including MMP-2, to form a 
soluble chemokine fragment, which acts as a chemoattractant for monocytes and other 
leukocytes (Dean & Overall, 2007). It has been postulated that the equilibrium between the 
cleaved and transmembrane forms directly impacts neuron growth and survival (Zieger et al., 
2014). However, the fragment has experimentally been shown to be subject to truncation by 
MMPs, specifically MMP-2. This truncation alters the function of the chemokine and may even 
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transform it into an antagonist to its own receptor, CX3CR1, thereby reducing inflammation 
(Dean & Overall, 2007). From this data, it is likely that MMP-9 could also induce fractalkine 
shedding and perhaps cleave the protein in another pattern that produces pro-inflammatory 
fragments. The research described in this study seeks to determine whether MMP-9 cleaves 
fractalkine on the surface of F11 neurons.  
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 METHODS 
Literature Review 
  A search of PubMed was conducted using keywords such as M1, macrophage, 
inflammation, spinal cord injury, and axon retraction. Studies were screened for relevance to the 
topic by reviewing abstracts. All irrelevant studies, as well as studies not available in English, 
were not included. Five studies were selected for review (Busch et al., 2009; Evans et al., 2014; 
Horn et al., 2008; Kigerl et al., 2009; Shechter et al., 2013). Findings concerning macrophage 
subtype gene expression and axon retraction timing after spinal cord injury were collected and 
summarized.  
Sterile Cell Culture  
The F11 (ECACC08062601) neuronal cell line was a generous gift from Dr. Jeff Twiss 
(University of South Carolina). The F11 cell line is a hybrid derived from rat embryonic DRG 
and mouse neuroblastoma N18TG2 cell lines. Subcultured cells are grown in 
DMEM/1%Penicillin-Streptomysin/10% Fetal Bovine Serum on 100mm tissue culture dishes in 
an incubator at 37ºC and 5% CO₂. Cultures are passaged at 70-80% confluence. Cells are washed 
using warmed Hank’s Balanced Salt Solution (HBSS) prior to dissociation, and dissociated with 
0.25% trypsin/EDTA/0.5% CO₂ warmed to 37ºC. Cells are centrifuged in new growth medium at 
2,000rpm for 5 minutes, then resuspended in growth medium once more before plating. The new 
culture should be diluted to approximately 2-4x10,000cells/cm².  
Treatment with MMP-9 
Active human recombinant MMP-9 (EC 3.4.24.35) was purchased from Sigma-Aldrich. 
Prior to experimentation, the enzyme was reconstituted in sterile DMSO to a final concentration 
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of 0.005μg/μl. Cells were plated three days prior to experimentation on 35mm tissue culture 
plates in Neurobasal-A/0.5mM Glutamax/1% B27/1% Penicillin-Streptomycin. This serum-free 
media allowed the F11 cells to differentiate. Forskolin was added at the time of plating to aid in 
neuron differentiation. On day four, pictures were taken using unfiltered light microscopy in 
order to analyze the length and branching of neurites. The media was removed, and 1.5ml of new 
media containing MMP-9 (or DMSO vehicle) was added to each experimental plate as shown 
below, so that 300 ng of MMP-9 was present in every milliliter of media. Since MMP-9 is used 
at a concentration of 0.005 ug/ul, 6ul of reconstituted MMP-9 or vehicle should be added for 
each 1ml of media. Plates were incubated at 37ºC for 2 hours, 6 hours, or 24 hours before the 
protein is collected from the plates (Figure 1). These time points should be sufficient to allow 
cleavage to occur, as cleavage of fractalkine has been measured at 3 hours and 48 hours in the 
past (Dean & Overall, 2007). 
Plate MMP-9 DMSO Incubation time 
(hours) 
1A - + 2 
1B + - 2 
2A - + 6 
2B + - 6 
3A - + 24 
3B + - 24 
Table 1: Treatment and incubation times for experimental tissue culture plates 
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Cell Lysis, Protein Collection, and Quantification 
After treatment and appropriate incubation time, the plates were placed on ice and media 
was collected from each of the plates into microfuge tubes. Protease inhibitor was added to the 
collected media. The plates were washed with cold 1X PBS before cold lysis buffer (50mM Tris-
HCl, pH7.5, 40 mM NaCl, 1mM EDTA, 0.5% Triton-X, 1X protease inhibitor) was added. Cells 
were removed using a cell scraper, and pipetted up-and-down to ensure complete lysis. The 
samples were separated via microcentrifuge for 20 minutes at 4ºC at max g. The supernatant was 
collected, and protein quantification of the supernatant was performed using Bradford assay 
measured via microplate reader. Samples are added to 2X Laemmli buffer (purchased from Bio-
rad), then normalized using 1X Laemmli buffer, so that at least 20ug of protein will be added to 
each lane on SDS-PAGE in a maximum of 25ul. Samples are then heat blocked for 5 minutes at 
95ºC, mixed by vortex, and frozen at -20ºC. 
Western Blot Assay  
Proteins were separated via SDS-PAGE on a 1 mm 12% polyacrylamide gel. After 
electrophoresis, bands were western transferred to a nitrocellulose membrane using standard 
protocol. The membrane was blocked with BLOTTO (5% non-fat milk in TBS-T) for one hour, 
then treated with primary antibody dissolved in BLOTTO. The primary antibody, used at 
1:1,000, is polyclonal rabbit IgG that targets the N-terminal chemokine domain of fractalkine 
(14-7986-81; ThermoFisher). Monoclonal mouse antibody was used at a concentration of 
1:1,000 to target beta tubulin III as a loading control (T5076; Sigma). The membrane was 
washed and rinsed, then incubated with fluorescent secondary antibodies. Goat anti-rabbit IgG 
StarBright Blue 700 was added at a concentration of 1:2,500 (12004161; BioRad), and goat anti-
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mouse IgG DyLight800 was added at a concentration of 1:10,000 (STAR117D800GA; BioRad). 
Results were visualized using ChemiDoc (BioRad), and the program ImageJ was used to 
quantify the amount of protein in the resulting bands (Schindelin et al., 2012). This experimental 
protocol was completed three times to confirm results.  Cleavage fragments were expected to be 
visualized on western blot as indicators of increased fractalkine cleavage by MMP-9 (Conant et 
al., 2017). A summary of this experimental protocol is shown in Figure 1. 
15 
 
 
 
Figure 1: Diagram of Experimental Method  
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RESULTS 
A Review of Macrophage Infiltration After Spinal Cord Injury 
 Five studies concerning the timing of macrophage infiltration of the spinal cord were 
selected for review (Busch et al., 2009; Evans et al., 2014; Horn et al., 2008; Kigerl et al., 2009; 
Shechter et al., 2013). These sources have gathered data showing temporal changes in expression 
of macrophage-specific markers, roughly summarized in Table 2. Most studies note a significant 
increase in blood-derived macrophages between 3 and 5 days post-injury and show that these 
levels remain elevated for almost a month after injury. ED-1, a general marker for macrophages, 
was found to be elevated from baseline on day 7, 14, and 28 post-injury, but not at 2 days post 
injury (Busch et al., 2009; Horn et al., 2008). Evans et al. (2014) found CX3CR1+ cells at levels 
elevated from baseline at 2, 5, and 8 days post injury, and observed that the number of blood-
derived macrophages begins to increase rapidly 2 hours after injury. The cells reportedly 
increased three fold from day 0-2 and 7 fold from day 0-8 (Evans et al., 2014). 
However, there is conflicting evidence related to the difference in M2 and M1 expression 
levels over time. For example, Kigerl et al. (2009) finds that most M1 markers are elevated on 
day 7 and remain elevated for up to 28 days post injury. However, iNOS was found to be 
elevated on day 1 and day 3 only. Furthermore, M2 markers CD206 and Arg I were found at 
elevated levels at completely different times. Nevertheless, the observed ratio of M1 to M2 
macrophages reportedly remained equal for the first week after injury but sharply increased on 
day 7 post injury. Shechter et al. (2013) found that cells expressing high levels of Ly6c, an M1 
marker, was elevated from day 1 through day 7, but declined by day 14. This study also found 
elevated levels of M2 markers longer after spinal cord injury than M1 markers. Cells expressing 
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high CX3CR1 and low Ly6c, characteristic of M2 macrophages, were observed at elevated 
levels on day 3 and remained elevated through day 14.  
 Using a limited number of markers to differentiate between M1 and M2 macrophages 
does not paint an accurate picture of the process of macrophage infiltration. One study found that 
a small percentage of macrophages expressed both M1 and M2 markers, suggesting that perhaps 
some conversion process was occurring (Evans et al., 2014). The infiltration process is highly 
dynamic and difficult to summarize.  
 Most studies noted the most significant axon retraction occurring on days 2-7 post injury, 
while also noting that retraction occurred up to 28 days post injury (Busch et al., 2009; Evans et 
al., 2014; Horn et al., 2008). Day 2 is likely when the first phase of dieback occurs, as noted by 
Horn et al. After day 2, the second phase of retraction begins, during which macrophages play a 
larger role. In fact, when macrophages were depleted, significantly less dieback occurred on days 
4 and 7 compared to control (Horn et al., 2008). During the second phase, some studies report 
that cellular contact with macrophages induced dieback 100% of the time, and no dieback was 
observed without cellular contact with macrophages (Busch et al., 2009; Evans et al., 2014; Horn 
et al., 2008). However, Evans et al. also noted that the number of non-destructive contacts was 
greater than the number of destructive contacts on all days post-injury. In other words, the 
number of contacts between macrophages and axons that resulted in dieback was significantly 
fewer than those that did not result in dieback after spinal cord injury.  
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   Days Post-Injury 
Reference Animal 
Model 
Macrophage-
Specific 
Marker 
1 2 3 4 5 7 8 14 28 
(Busch et 
al., 2009) 
Rat 
SCI 
ED-1  -  ↑  ↑  ↑ ↑ 
(Horn et 
al., 2008) 
Rat 
SCI 
ED-1  -  -  ↑  ↑ ↑ 
(Evans et 
al., 2014) 
Rat 
SCI 
CX3CR1  ↑   ↑  ↑   
CD11b     ↑     
(Kigerl et 
al., 2009) 
Mouse 
SCI 
CD86* -  -   -  - ↑ 
iNOS* ↑  ↑   -  - - 
CD16* -  -   ↑  ↑ ↑ 
CD32* -  -   ↑  ↑ ↑ 
CD206† -  -   ↑  ↑ - 
Arg I† ↑  ↑   -  - - 
(Shechter 
et al., 
2013) 
Mouse 
SCI 
Ly6c (hi) * ↑  ↑  ↑ ↑  -  
CX3CR1 (hi)† -  ↑  ↑ ↑  ↑  
Table 2: Summary of macrophage infiltration after spinal cord injury. This table aims to summarize the time points 
after spinal cord injury at which macrophage-specific markers are found at elevated levels at the area of injury 
compared to baseline.  
↑ =increased compared to baseline; - =no significant increase from baseline; * =marker specific to M1 macrophage 
subtype; † =marker specific to M2 macrophage subtype 
 
 
Figure 2: Graphical representation of macrophage-specific markers found at specific time intervals after spinal cord 
injury. Colored area reflects measurements significantly elevated from baseline. Macrophage-specific markers 
(black), M1 specific markers (light blue), and M2 specific markers (dark blue) are included. Gray areas reflect 
conflicting findings from multiple studies.  
 Days Post Injury 
Macrophage Specific 
Marker 1 2 3 4 5 7 8 14 28 
ED-1      1 0 1 0 1 
CX3CR1    1     1     
CD86           
iNOS             
CD16              
CD32              
CD206             
Arg I             
Ly6c (hi)                 
CX3CR1 (hi)                
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Cell Morphology 
 Prior to collection of protein samples, images were collected using light microscopy to 
document cell morphology before and after treatment. As shown in Figure 2, there were no 
dramatic changes observed in soma or neurite morphology after treatment with MMP-9 or 
vehicle for 24 hours. F11 cells maintain long, branching neurites after treatment. These results 
were similar to those obtained after 2 and 6 hours of treatment.  
  
  
Figure 3: Light microscopy captures morphology of differentiated F11 neurons before and after 24 hours of 
treatment. Pictures in the top panel were taken before (A) and after (B) treatment with DMSO for 24 hours. The 
bottom panel images were taken before (C) and after (D) treatment with MMP-9 for 24 hours. Arrowheads indicate 
cell bodies, and arrows indicate neurites.  
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Measurement of Total Fractalkine after Western Blot 
F11 neurons were grown in Neurobasal-A media containing either 300 ng/ml MMP-9 or 
DMSO vehicle for 2, 6, or 24 hours. Protein samples were collected at the end of each respective 
time interval and separated via SDS-PAGE. Proteins were transferred to a nitrocellulose 
membrane for western blot to detect fractalkine. Anti-β-tubulin III antibodies were included to 
detect β-tubulin III as a loading control. Upon observation of the resulting membranes after 
fluorescent visualization, it is apparent that the banding pattern of fractalkine is relatively 
uniform across each lane. An array of bands ranging from ~100kDa to ~17.5kDa was expected 
due to the multiple glycosylations typical of the protein and the natural shedding of the 
chemokine domain (Dean & Overall, 2007; Zieger et al., 2014). ImageJ was used to analyze the 
total amount of fractalkine and tubulin found in each lane. The ratio of fractalkine to tubulin was 
calculated for each lane in order to normalize the amount of fractalkine to the total protein loaded 
onto the gel based on the tubulin loading control. The mean was taken for all three trials and 
displayed graphically with the standard deviation (Figure 3E). An outlier was omitted from the 
average fractalkine after treatment with MMP-9 for 6 hours, which caused a large variability in 
this data point.  
 Anti-fractalkine antibodies targeted the extracellular portion of the protein. It was 
expected that if MMP-9 cleaved fractalkine, fragments would be detected in the media sample 
and less total fractalkine would be present in the lysate. There are no bands visible in the media 
lanes, and ImageJ was used to confirm the lack of fragments able to be detected. Several trends 
can be observed regarding the total fractalkine in the cell lysate. First, there seems to be a 
reduction in the total amount of fractalkine between 2 and 24 hours regardless of treatment. 
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Second, there is a possible reduction in total fractalkine after treatment with MMP-9 for 2 hours 
compared to control treatment. Finally, after 24 hours, there seems to be no difference in the total 
fractalkine found in the control and MMP-9 treatment groups.   
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Figure 4: Western Blot Results. The collected media (M) and cell lysate (L) samples were probed using fluorescent 
antibodies. Exposure of the trial 1 blots at a 700 nm wavelength allows for visualization of targeted fractalkine 
(A,B). Exposure of the same blot at 800 nm wavelength shows targeted β-tubulin III (C,D). Bands from all trials 
were quantified using ImageJ, and the average ratio of fractalkine to tubulin for each condition was plotted plus or 
minus one standard deviation (E). After 2 hours, cells treated with DMSO had an average fractalkine/tubulin ratio of 
7.179±1.611 and cells treated with MMP-9 had a ratio of 4.974±2.010. After 6 hours, cells treated with DMSO had 
an average ratio of 4.482±2.319 and cells treated with MMP-9 had a ratio of 5.916±5.026. After 24 hours, cells 
treated with DMSO had an average ratio of 2.542±0.678 and cells treated with MMP-9 had a ratio of 2.505±0.483. 
These results are shown graphically above (E). 
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DISCUSSION 
 After 2 hours, 6 hours, and 24 hours, there was no evidence of fractalkine fragments in 
the media samples collected (Figure 3). However, a trend suggests a possible decrease in 
fractalkine in the cell lysate after 2 hours compared to control, but not 24 hours. This could 
suggest that MMP-9 is only able to acutely affect fractalkine shedding. However, because the 
control and experimental measurements were relatively close, the data could also suggest that at 
a concentration of 300 ng/ml, MMP-9 has no effect on fractalkine cleavage. Due to the limited 
number of trials performed, it is difficult to draw many conclusions from the data obtained from 
western blot and imaging. 
 Previous studies have shown that M1 macrophages induce axon dieback through direct 
contact involving MMP-9 (Busch et al., 2009; Garcia et al., 2016; Horn et al., 2008). However, 
the full mechanism behind this is not entirely clear. N-cadherins, β1-integrins, and other proteins 
on the neuronal membrane have been suggested to play a role (Conant et al., 2017; Kim et al., 
2009). Had fractalkine been cleaved by MMP-9 in this experiment, it could have been 
hypothesized that MMP-9 induces dieback in axons in part through its cleavage of fractalkine. If 
the results are truly negative, it can be deduced that fractalkine does not play a role in dieback 
directly induced by MMP-9.   
 If cleavage fragments were produced, it may have been an interesting extension of this 
experiment to observe the effect of these cleavage fragments on neuron growth. As discussed in 
previous sections, fractalkine is known to be cleaved by MMP-2 to produce a chemokine 
fragment. Further truncation by MMP-2 alters the function of the chemokine and may even 
transform it into an antagonist to its own receptor, CX3CR1, thereby reducing inflammation 
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(Dean & Overall, 2007). It is likely that MMP-9 could also induce fractalkine shedding and 
perhaps cleave the protein in another pattern that produces pro-inflammatory fragments. The 
cytokine fragments may produce a paracrine signal that exacerbates damage. Further 
optimization and research should be done in order to increase our understanding of the role of 
MMP-9 in exacerbation of spinal cord injury. 
Several improvements could be made to this protocol. First and foremost, decreasing the 
amount of noise during fluorescent visualization of western blot could increase the accuracy of 
the results. Minimizing contamination, increasing blocking time, and optimizing antibody 
dilutions could significantly reduce noise when visualizing the blot at 700 nm. Ensuring the 
absence of air bubbles during western transfer could improve the accuracy of the transfer. These 
procedures could in turn increase the accuracy of ImageJ measurements by decreasing the noise 
to signal ratio. Furthermore, increasing the number of trials would allow for more effective 
statistical analysis of the data acquired.  
 Perhaps devising a way to remove glycosylations from CX3CL1 could help standardize 
the molecular weight of the protein and make it easier to detect cleavage. Running SDS-PAGE 
for a longer period of time may have allowed for better separation and visualization of larger 
fragments. Furthermore, if the cleavage fragments produced by MMP-9 were of an extremely 
small molecular weight, they may have been lost during western transfer, and optimizing this 
procedure may also help with visualization. It is also possible that concentrating the media 
samples could have allowed for better visualization of any fragments cleaved. If only a small 
amount of fragments were produced, the media may have been too dilute for proper 
visualization. Higher concentrations of MMP-9 may have also been useful. A concentration of 
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300 ng/ml may have been too low to produce significant changes. Finally, a positive control, 
such as treatment with MMP-2, may provide more insight to negative results.  
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